| FGFR4: A promising therapeutic target for breast cancer and other solid tumors KM Levine, K Ding, L Chen, S Oesterreich Pharmacology & therapeutics 214, 107590, 2020 | 65 | 2020 |
| Efficient generation of bispecific IgG antibodies by split intein mediated protein trans-splicing system L Han, J Chen, K Ding, H Zong, Y Xie, H Jiang, B Zhang, H Lu, W Yin, ... Scientific Reports 7 (1), 8360, 2017 | 64 | 2017 |
| FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype KM Levine, N Priedigkeit, A Basudan, N Tasdemir, MJ Sikora, ES Sokol, ... NPJ breast cancer 5 (1), 19, 2019 | 59 | 2019 |
| ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation Z Li, O McGinn, Y Wu, A Bahreini, NM Priedigkeit, K Ding, S Onkar, ... Nature Communications 13 (1), 2011, 2022 | 43 | 2022 |
| Single-cell transcriptomic heterogeneity in invasive ductal and lobular breast cancer cells F Chen, K Ding, N Priedigkeit, A Elangovan, KM Levine, N Carleton, ... Cancer research 81 (2), 268-281, 2021 | 38 | 2021 |
| Production process reproducibility and product quality consistency of transient gene expression in HEK293 cells with anti-PD1 antibody as the model protein K Ding, L Han, H Zong, J Chen, B Zhang, J Zhu Applied microbiology and biotechnology 101, 1889-1898, 2017 | 36 | 2017 |
| Producing defucosylated antibodies with enhanced in vitro antibody‐dependent cellular cytotoxicity via FUT8 knockout CHO‐S cells H Zong, L Han, K Ding, J Wang, T Sun, X Zhang, C Cagliero, H Jiang, ... Engineering in Life Sciences 17 (7), 801-808, 2017 | 26 | 2017 |
| Enhanced production of anti-PD1 antibody in CHO cells through transient co-transfection with anti-apoptotic genes Bcl-x L and Mcl-1 X Zhang, L Han, H Zong, K Ding, Y Yuan, J Bai, Y Zhou, B Zhang, J Zhu Bioprocess and biosystems engineering 41, 633-640, 2018 | 25 | 2018 |
| Naturally split intein Npu DnaE mediated rapid generation of bispecific IgG antibodies L Han, H Zong, Y Zhou, Z Pan, J Chen, K Ding, Y Xie, H Jiang, B Zhang, ... Methods 154, 32-37, 2019 | 23 | 2019 |
| Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences N Priedigkeit, K Ding, W Horne, JK Kolls, T Du, PC Lucas, JU Blohmer, ... Breast Cancer Research 23, 1-14, 2021 | 22 | 2021 |
| Proteomic and transcriptomic profiling identifies mediators of anchorage-independent growth and roles of inhibitor of differentiation proteins in invasive lobular carcinoma N Tasdemir, K Ding, L Savariau, KM Levine, T Du, A Elangovan, ... Scientific Reports 10 (1), 11487, 2020 | 20 | 2020 |
| Single cell heterogeneity and evolution of breast cancer bone metastasis and organoids reveals therapeutic targets for precision medicine K Ding, F Chen, N Priedigkeit, DD Brown, K Weiss, R Watters, KM Levine, ... Annals of Oncology 33 (10), 1085-1088, 2022 | 13 | 2022 |
| p38MAPKα stromal reprogramming sensitizes metastatic breast cancer to immunotherapy DV Faget, X Luo, MJ Inkman, Q Ren, X Su, K Ding, MR Waters, GK Raut, ... Cancer discovery 13 (6), 1454-1477, 2023 | 7 | 2023 |
| Kinetics study of the natural split Npu DnaE intein in the generation of bispecific IgG antibodies H Zong, L Han, J Chen, Z Pan, L Wang, R Sun, K Ding, Y Xie, H Jiang, ... Applied Microbiology and Biotechnology 106 (1), 161-171, 2022 | 6 | 2022 |
| Construction of novel bispecific single-domain antibodies (BiSdAbs) with potent antiangiogenic activities X Liu, T Sun, Q Ge, J Zhu Pharmaceutical Fronts 2 (01), e64-e76, 2020 | 6 | 2020 |
| Isoforms of neuropilin-2 denote unique tumor-associated macrophages in breast cancer R Dhupar, KE Jones, AA Powers, SH Eisenberg, K Ding, F Chen, ... Frontiers in Immunology 13, 830169, 2022 | 4 | 2022 |
| Semi-deconvolution of bulk and single-cell RNA-seq data with application to metastatic progression in breast cancer H Lei, XA Guo, Y Tao, K Ding, X Fu, S Oesterreich, AV Lee, R Schwartz Bioinformatics 38 (Supplement_1), i386-i394, 2022 | 2 | 2022 |
| Generating a novel bispecific nanobody to enhance antitumor activity Q Ge, T Sun, Y Bian, X Xiao, J Zhu Pharmaceutical Fronts 2 (02), e100-e108, 2020 | 2 | 2020 |
| WCRC-25: A novel luminal Invasive Lobular Carcinoma cell line model A Elangovan, EA Bossart, A Basudan, N Tasdemir, OS Shah, K Ding, ... bioRxiv, 2023.09. 15.558023, 2023 | 1 | 2023 |
| Abstract P5-12-03: Wcrc-25: A novel luminal invasive lobular carcinoma cell line model A Elangovan, EA Bossart, A Basudan, N Tasdemir, OS Shah, K Ding, ... Cancer Research 82 (4_Supplement), P5-12-03-P5-12-03, 2022 | 1 | 2022 |
